Funding for this research was provided by:
Canada Excellence Research Chairs, Government of Canada (F18-03211)
Received: 7 December 2021
Accepted: 21 July 2022
First Online: 18 August 2022
: Z.S., W.L., J.W.M., and D.S.D. are coinventors of a patent, filed by the University of Pittsburgh, related to ab6, ab1, and ab8 that were assessed in this manuscript. S.S. is the Founder and CEO of Gandeeva Therapeutics Inc. The remaining authors declare no competing interests.